<DOC>
	<DOCNO>NCT03069144</DOCNO>
	<brief_summary>Psoriasis , prevalent autoimmune disease U.S. , manifest plaque type psoriasis vulgaris lesion localize scalp , postauricular region , face , diaper area , elbow , knee . Inadequately controlled disease common significant cause extensive psychological clinical morbidity child . In addition , safety tolerability issue common treatment psoriasis include topical corticosteroid , calcipotriol , oral cytotoxic drug , biologic agent especially problematic patient limit use . Identification therapy high efficacy safety profile suitable patient psoriasis therefore area critical unmet need . Haus Bioceuticals develop topical treatment psoriasis denote HAT1 ( base ingredient establish clinical benefit ) , demonstrate HAT1 safe profoundly effective treatment psoriasis . This study aim evaluate efficacy safety HAT1 compare commonly use calcipotriol patient mild moderate chronic plaque psoriasis .</brief_summary>
	<brief_title>Efficacy Tolerability HAT1 Compared Calcipotriol Patients With Mild Moderate Chronic Plaque Psoriasis</brief_title>
	<detailed_description>This study exploratory 10-week open-label clinical study design evaluate efficacy safety HAT1 compare calcipotriol adult patient mild moderate chronic plaque psoriasis . The study include subject age 18 - 65 year old inclusive . Group assignments balanced disease severity , age , body location lesion . The study consist 1 week washout period 12 week treatment phase . During treatment phase , subject provide one two labeled test product HAT1 calcipotriol use twice daily lesion non-lesional area instruct . No additional cream , lotion soap provide test product allow throughout duration study . There also consumption/compliance check dermatological evaluation visit .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Clinical diagnosis psoriasis psoriasis area severity index ( PASI ) score &gt; 3 &lt; 12 Treatment area amenable topical treatment Attending hospital outpatient clinic private practice dermatologist Males Females 1865 year Systemic treatment immunosuppressive drug corticosteroid within 4 week prior enrollment . ( Inhaled intranasal steroid asthma rhinitis may use ) Topical treatment immunomodulators corticosteroid within 4 week prior enrollment . Phototherapy therapy within 4 week prior enrollment topical therapy treatment area within 1 week prior enrollment . Patients require topical systemic medication could affect course psoriasis study period . Clinical infection treatment area patient history cancer include skin cancer , history immunocompromised disease . Current participation interventional clinical trial History allergy component HAT1 previously treat HAT1 Subjects intense sun exposure study Patients know suspect able comply trial protocol ( e.g . alcoholism , drug dependency , psychotic state ) Patients currently pregnant lactate plan become pregnant next 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Topical</keyword>
</DOC>